Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer
AC Garrido-Castro, C Saura, R Barroso-Sousa… - Breast Cancer …, 2020 - Springer
AC Garrido-Castro, C Saura, R Barroso-Sousa, H Guo, E Ciruelos, B Bermejo, J Gavilá…
Breast Cancer Research, 2020•SpringerBackground Treatment options for triple-negative breast cancer remain limited. Activation of
the PI3K pathway via loss of PTEN and/or INPP4B is common. Buparlisib is an orally
bioavailable, pan-class I PI3K inhibitor. We evaluated the safety and efficacy of buparlisib in
patients with metastatic triple-negative breast cancer. Methods This was a single-arm phase
2 study enrolling patients with triple-negative metastatic breast cancer. Patients were treated
with buparlisib at a starting dose of 100 mg daily. The primary endpoint was clinical benefit …
the PI3K pathway via loss of PTEN and/or INPP4B is common. Buparlisib is an orally
bioavailable, pan-class I PI3K inhibitor. We evaluated the safety and efficacy of buparlisib in
patients with metastatic triple-negative breast cancer. Methods This was a single-arm phase
2 study enrolling patients with triple-negative metastatic breast cancer. Patients were treated
with buparlisib at a starting dose of 100 mg daily. The primary endpoint was clinical benefit …
Background
Treatment options for triple-negative breast cancer remain limited. Activation of the PI3K pathway via loss of PTEN and/or INPP4B is common. Buparlisib is an orally bioavailable, pan-class I PI3K inhibitor. We evaluated the safety and efficacy of buparlisib in patients with metastatic triple-negative breast cancer.
Methods
This was a single-arm phase 2 study enrolling patients with triple-negative metastatic breast cancer. Patients were treated with buparlisib at a starting dose of 100 mg daily. The primary endpoint was clinical benefit, defined as confirmed complete response (CR), partial response (PR), or stable disease (SD) for ≥ 4 months, per RECIST 1.1. Secondary endpoints included progression-free survival (PFS), overall survival (OS), and toxicity. A subset of patients underwent pre- and on-treatment tumor tissue biopsies for correlative studies.
Results
Fifty patients were enrolled. Median number of cycles was 2 (range 1–10). The clinical benefit rate was 12% (6 patients, all SD ≥ 4 months). Median PFS was 1.8 months (95% confidence interval [CI] 1.6–2.3). Median OS was 11.2 months (95% CI 6.2–25). The most frequent adverse events were fatigue (58% all grades, 8% grade 3), nausea (34% all grades, none grade 3), hyperglycemia (34% all grades, 4% grade 3), and anorexia (30% all grades, 2% grade 3). Eighteen percent of patients experienced depression (12% grade 1, 6% grade 2) and anxiety (10% grade 1, 8% grade 2). Alterations in PIK3CA/AKT1/PTEN were present in 6/27 patients with available targeted DNA sequencing (MSK-IMPACT), 3 of whom achieved SD as best overall response though none with clinical benefit ≥ 4 months. Of five patients with paired baseline and on-treatment biopsies, reverse phase protein arrays (RPPA) analysis demonstrated reduction of S6 phosphorylation in 2 of 3 patients who achieved SD, and in none of the patients with progressive disease.
Conclusions
Buparlisib was associated with prolonged SD in a very small subset of patients with triple-negative breast cancer; however, no confirmed objective responses were observed. Downmodulation of key nodes in the PI3K pathway was observed in patients who achieved SD. PI3K pathway inhibition alone may be insufficient as a therapeutic strategy for triple-negative breast cancer.
Trial registration
NCT01790932 . Registered on 13 February 2013; NCT01629615 . Registered on 27 June 2012.
Springer